Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 2,100 shares, a decline of 98.4% from the February 29th total of 134,400 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 28,800 shares, the days-to-cover ratio is currently 0.1 days.
Moleculin Biotech Price Performance
NASDAQ MBRX traded up $0.37 during trading on Thursday, hitting $5.91. The company’s stock had a trading volume of 77,998 shares, compared to its average volume of 31,255. The business’s 50 day simple moving average is $7.88 and its 200-day simple moving average is $8.23. The company has a market cap of $13.18 million, a PE ratio of -0.44 and a beta of 1.98. Moleculin Biotech has a fifty-two week low of $4.34 and a fifty-two week high of $24.75.
Hedge Funds Weigh In On Moleculin Biotech
Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. acquired a new position in Moleculin Biotech during the 4th quarter worth $39,000. Atticus Wealth Management LLC acquired a new position in Moleculin Biotech in the fourth quarter valued at $43,000. Citadel Advisors LLC acquired a new position in Moleculin Biotech during the fourth quarter worth approximately $55,000. Renaissance Technologies LLC raised its holdings in shares of Moleculin Biotech by 34.7% in the second quarter. Renaissance Technologies LLC now owns 127,400 shares of the company’s stock valued at $74,000 after buying an additional 32,795 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Moleculin Biotech by 19.2% during the first quarter. State Street Corp now owns 71,397 shares of the company’s stock worth $127,000 after purchasing an additional 11,497 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
View Our Latest Stock Report on Moleculin Biotech
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
Further Reading
- Five stocks we like better than Moleculin Biotech
- Upcoming IPO Stock Lockup Period, Explained
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What Is Dividend Yield and How Do You Calculate It?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is a Stock Market Index and How Do You Use Them?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.